Seeking Alpha EN

Verrica Pharmaceuticals Non-GAAP EPS of -$1.24 misses by $0.82, revenue of $35.58M beats by $0.58M

Mar 11, 2026 &03091111202631; 12:09 UTC seekingalpha.com Trending 3/5

Read original on seekingalpha.com ↗

↘

Negative for markets

Sentiment score: -65/100

Moderate impact Short-term (days)

WHAT THIS MEANS

Verrica Pharmaceuticals reported Q3 results with non-GAAP EPS of -$1.24, significantly missing analyst expectations by $0.82, though revenue of $35.58M slightly exceeded estimates by $0.58M. The substantial EPS miss indicates profitability challenges despite modest revenue beat, suggesting operational efficiency concerns.

AI CONFIDENCE

75% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↓

VRCA

VRCAStock

Expected to decline

Large EPS miss of $0.82 indicates significant profitability gap despite revenue beat; negative non-GAAP earnings signal operational challenges

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Consider reducing exposure to VRCA on the earnings miss; the substantial EPS shortfall outweighs the modest revenue beat, suggesting deteriorating unit economics. Monitor guidance and cash burn rate in upcoming conference call for potential downside risks.

KEY SIGNALS

EPS miss significantly exceeds revenue beat magnitudeNegative non-GAAP earnings indicate margin compressionRevenue growth insufficient to offset cost structureProfitability trajectory remains challenged

SECTORS INVOLVED

HealthcarePharmaceuticalsBiotechnology

Analysis generated on Mar 12, 2026 at 01:31 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by Seeking Alpha. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Verrica Pharmaceuticals Non-GAAP EPS of -$1.24 misses by $0.82, revenue of $35.58M beats by $0.58M

RELATED INTELLIGENCE